Patents Assigned to CGENETECH (SUZHOU, CHINA) CO., LTD.
  • Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same
    Patent number: 11396501
    Abstract: The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: July 26, 2022
    Assignee: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Xiaohu Zhang, Jiyue Zheng, Haikuo Ma
  • Salt of cetagliptin, preparation method thereof, pharmaceutical composition, and use thereof
    Patent number: 11046701
    Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: June 29, 2021
    Assignee: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Yan Hao, Renyan Zhang, Huiping Pan, Fuzhi Zhang, Shijie Yin, Juping Ding, Qiang Yu
  • SALT OF CETAGLIPTIN, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION, AND USE THEREOF
    Publication number: 20200123164
    Abstract: The present invention relates to a salt of a compound of formula (I), The salt is crystalline or amorphous phosphate, or crystalline or amorphous oxalate. Particularly, a crystal form B of the phosphate of the present invention has high crystallinity, low hygroscopicity and good stability, and the crystal form B of the phosphate is good in oral bioavailability, good in tolerance after long-term administration, difficult to induce hypoglycemia and good in inhibition effect on serum DPPIV.
    Type: Application
    Filed: May 29, 2018
    Publication date: April 23, 2020
    Applicant: CGENETECH (SUZHOU, CHINA) CO., LTD.
    Inventors: Yan HAO, Renyan ZHANG, Huiping PAN, Fuzhi ZHANG, Shijie YIN, Juping DING, Qiang YU